Mouse Models of IM

$366,267P01FY2007CANIH

Icahn School Of Medicine At Mount Sinai, New York NY

Investigators

Linked publications & trials

Paper 39532065 Paper 39062946 Paper 38824647 Paper 38772686 Paper 38720070 Paper 38230747 Paper 38117649 Paper 37992313 Paper 37871309 Paper 37553354 Paper 37528578 Paper 37459200 Paper 37439808 Paper 37425686 Paper 37188088 Paper 36863479 Paper 36800567 Paper 36728649 Paper 36537918 Paper 36309559 Paper 36283106 Paper 36191885 Paper 36054916 Paper 35861015 Paper 35421216 Paper 35365653 Paper 35204735 Paper 35167654 Paper 35007321 Paper 34971581 Paper 34943811 Paper 34804309 Paper 34721069 Paper 34707640 Paper 34699595 Paper 34685741 Paper 34674293 Paper 34642468 Paper 34557872 Paper 34480104 Paper 34383713 Paper 34320782 Paper 34087176 Paper 33925695 Paper 33817698 Paper 33782031 Paper 33762108 Paper 33731931 Paper 33641878 Paper 33641866 Paper 33641863 Paper 33641861 Paper 33579786 Paper 33381905 Paper 33312951 Paper 33237986 Paper 33216890 Paper 33104796 Paper 32956452 Paper 32915487 Paper 32669286 Paper 32619551 Paper 32606137 Paper 32430500 Paper 32417942 Paper 32399971 Paper 32238463 Paper 32160610 Paper 32107559 Paper 31824842 Paper 31811055 Paper 31750881 Paper 31749302 Paper 31711337 Paper 31678370 Paper 31587352 Paper 31583083 Paper 31515250 Paper 31363161 Paper 31270458 Paper 31266769 Paper 31217200 Paper 31167802 Paper 30730307 Paper 30668266 Paper 30655313 Paper 30625392 Paper 30563882 Paper 30563881 Paper 30429377 Paper 30242099 Paper 30205231 Paper 29776986 Paper 29748436 Paper 29700354 Paper 29634952 Paper 29519804 Paper 29400094 Paper 29248611 Paper 29218307

Abstract

We propose to use the GATA-1low murine model as a tool to define the biologic mechanisms underlying the[unreadable] abnormal hematopoietic stem cell (HSC) and progenitor cell (HPC) trafficking and extramedullary[unreadable] hemopoiesis that characterizes idiopathic myelofibrosis (IM) and identify new targets for the development of[unreadable] drugs to treat this disorder. During this project we will test the hypothesis that HSC/HPC mobilization occurs[unreadable] at specific stages of the disease and that abnormal cell trafficking requires either the generation of a specific[unreadable] cell type (the extramedullary hematopoietic initiating cell, EMH-IC) or mobilization of both HSC/EPC and[unreadable] mesenchymal stem cells (MSC) and/or endothelial progenitor cells (EPC), responsible for generating a[unreadable] permissive hematopoietic microenvironment in a variety of extramedullary sites. To test this hypothesis we[unreadable] will:[unreadable] Specific Aim 1) To characterize the degree of HSC/HPC and MSC/EPC mobilization and trafficking during[unreadable] the course of the development of myelofibrosis in GATA-1low mice.[unreadable] Specific Aim 2) To identify the mechanisms underlying the development of abnormal HSC/HPC trafficking[unreadable] and extramedullary hemopoiesis in GATA-1low mice.[unreadable] Specific Aim 3) To identify treatment strategies for the treatment of each stage of the disease in GATA-1low[unreadable] mice.[unreadable] Relevance: IM is a hematological malignancy associated with abnormal stem cell trafficking and increased[unreadable] extramedullary hematopoiesis. We believe that a side-by-side investigation of the mechanisms leading to[unreadable] abnormal HSC/HPC trafficking and extramedullary hematopoiesis in the mouse model (Project 4) and IM[unreadable] patients (Project 5) will represent a powerful and effective approach to identify the optimal treatment for IM.

View original record on NIH RePORTER →